Galera Therapeutics Files Q1 2025 10-Q
Ticker: GRTX · Form: 10-Q · Filed: May 15, 2025 · CIK: 1563577
Sentiment: neutral
Topics: 10-Q, financials, stock-plans, pharmaceutical
Related Tickers: GRTX
TL;DR
Galera Therapeutics (GRTX) Q1 2025 10-Q filed. Stock, capital, and award plans detailed.
AI Summary
Galera Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition, including details on common stock, preferred stock, and additional paid-in capital. Key events and plans mentioned include the Employment Inducement Award Plan and royalty agreements.
Why It Matters
This filing provides investors with an update on Galera Therapeutics' financial health and operational activities for the first quarter of 2025, including details on stock and award plans.
Risk Assessment
Risk Level: medium — The filing is a standard quarterly report, but the company operates in the volatile pharmaceutical sector.
Key Numbers
- 2025-03-31 — Reporting Period End Date (The 10-Q covers financial activities up to this date.)
- 2025-05-15 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2024-12-31 — Previous Fiscal Year End (Provides a comparison point for financial data.)
Key Players & Entities
- Galera Therapeutics, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- 101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA 19355 (address) — Company business and mailing address
- 610-725-1500 (phone_number) — Company business phone
- Nova Pharmaceuticals Inc. (company) — Mentioned in relation to the reporting period
- Dr. Chang (person) — Associated with Series B Preferred Stock and reporting period
- Mr. Friedman (person) — Associated with reporting period
FAQ
What is the primary business of Galera Therapeutics, Inc.?
Galera Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the fiscal year end for Galera Therapeutics, Inc.?
The company's fiscal year ends on December 31st.
What specific stock types are mentioned in the filing?
The filing mentions us-gaap:CommonStockMember, us-gaap:SeriesBPreferredStockMember, and us-gaap:PreferredStockMember.
What award plans are referenced in the filing?
The filing references grtx:EmploymentInducementAwardPlanMember, grtx:TwoThousandNineteenIncentiveAwardPlanMember, and grtx:ThousandAndNineteenEmployeeStockPurchasePlanMember.
What is the company's state of incorporation?
Galera Therapeutics, Inc. is incorporated in Delaware (DE).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 by Dr. Chang regarding Galera Therapeutics, Inc. (GRTX).